Company intelligence / Profile preview
GenieBiome
- Ownership
- Private
- Employees
- ~50
- Development stage
- Commercial
Overview
GenieBiome has developed a portfolio of precision diagnostic tests and next-generation probiotic/microbiome formulas supported by clinical research. Their solutions target a range of diseases with unmet needs in the Asian population. They have demonstrated scientific results such as predicting durable immunity post-vaccination using baseline gut microbiota/metabolomic profiles.[1][2][4]
- Therapeutic areas
- OncologyMetabolic DisordersImmunologyPsychiatryDermatologyGastroenterology
- Modalities
- Microbiome-based therapeutics (precision microbiome formulas)Probiotic products and natural active bacteria therapiesDiagnostic tests based on metagenomics/bioinformatics platforms
- Industry
- Biotech
Drug pipeline
6 assets5 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on GenieBiome.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GenieBiome.